

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Heinrich HAAS <i>et al.</i>)	Confirmation No: 6810
)	
Application No. 10/519,193)	Group Art Unit: 1615
)	
Filed: December 21, 2005)	Examiner: Gollamudi Kishore
)	
For: CAMPTOTHECIN-CARBOXYLATE)	Date: August 14, 2007
FORMULATIONS)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.


Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: **August 14, 2007**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Sally P. Teng, Ph.D.
Registration No. 45,397

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.
062587-5003

Application No. 10/519,193

Applicants: **Heinrich HAAS *et al.***

PAGE 1 of 1

Filing Date: **December 21, 2005**

Group Art Unit: 1615

U.S. PATENT DOCUMENTS

DISPARATE DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 1. | Folkman, J et al. "Angiogenic factors" Science, 235(4787), pp 442-447 (1987) |
| 2. | Folkman, J. "Angiogenesis in cancer, vascular, rheumatoid and other disease" Nat. Med., 1(1), pp 27-31 (1995) |
| 3. | Griffioen, A et al. "Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation" Pharmacol Rev., 52(2), pp 237-268 (2000) |

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.